362 related articles for article (PubMed ID: 26864110)
1. Immunogenicity of therapeutic recombinant immunotoxins.
Mazor R; Onda M; Pastan I
Immunol Rev; 2016 Mar; 270(1):152-64. PubMed ID: 26864110
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of Immunotoxins Containing
Mazor R; Pastan I
Front Immunol; 2020; 11():1261. PubMed ID: 32695104
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
[TBL] [Abstract][Full Text] [Related]
4. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.
Mazor R; Eberle JA; Hu X; Vassall AN; Onda M; Beers R; Lee EC; Kreitman RJ; Lee B; Baker D; King C; Hassan R; Benhar I; Pastan I
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8571-6. PubMed ID: 24799704
[TBL] [Abstract][Full Text] [Related]
5. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
[TBL] [Abstract][Full Text] [Related]
6. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.
Hansen JK; Weldon JE; Xiang L; Beers R; Onda M; Pastan I
J Immunother; 2010 Apr; 33(3):297-304. PubMed ID: 20445350
[TBL] [Abstract][Full Text] [Related]
7. Higher cytotoxicity of divalent antibody-toxins than monovalent antibody-toxins.
Won J; Nam P; Lee Y; Choe M
Biochem Biophys Res Commun; 2009 Apr; 382(1):15-20. PubMed ID: 19245794
[TBL] [Abstract][Full Text] [Related]
8. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
9. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
Weldon JE; Pastan I
FEBS J; 2011 Dec; 278(23):4683-700. PubMed ID: 21585657
[TBL] [Abstract][Full Text] [Related]
10. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
Mazor R; Onda M; Park D; Addissie S; Xiang L; Zhang J; Hassan R; Pastan I
Oncotarget; 2016 May; 7(21):29916-26. PubMed ID: 27167198
[TBL] [Abstract][Full Text] [Related]
11. Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins.
Roscoe DM; Pai LH; Pastan I
Eur J Immunol; 1997 Jun; 27(6):1459-68. PubMed ID: 9209499
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.
King EM; Mazor R; Çuburu N; Pastan I
J Immunol; 2018 Mar; 200(6):2038-2045. PubMed ID: 29431691
[TBL] [Abstract][Full Text] [Related]
13. Removing T-cell epitopes with computational protein design.
King C; Garza EN; Mazor R; Linehan JL; Pastan I; Pepper M; Baker D
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8577-82. PubMed ID: 24843166
[TBL] [Abstract][Full Text] [Related]
14. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.
Mazor R; Vassall AN; Eberle JA; Beers R; Weldon JE; Venzon DJ; Tsang KY; Benhar I; Pastan I
Proc Natl Acad Sci U S A; 2012 Dec; 109(51):E3597-603. PubMed ID: 23213206
[TBL] [Abstract][Full Text] [Related]
15. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
Du X; Ho M; Pastan I
J Immunother; 2007 Sep; 30(6):607-13. PubMed ID: 17667524
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
Mazor R; Zhang J; Xiang L; Addissie S; Awuah P; Beers R; Hassan R; Pastan I
Mol Cancer Ther; 2015 Dec; 14(12):2789-96. PubMed ID: 26443804
[TBL] [Abstract][Full Text] [Related]
17. Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with
Nguyen MQ; Kim DH; Shim HJ; Ta HKK; Vu TL; Nguyen TKO; Lim JC; Choe H
Mol Cells; 2023 Dec; 46(12):764-777. PubMed ID: 38052492
[TBL] [Abstract][Full Text] [Related]
18. Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.
Kaplan G; Lee F; Onda M; Kolyvas E; Bhardwaj G; Baker D; Pastan I
Toxins (Basel); 2016 Jul; 8(8):. PubMed ID: 27463727
[TBL] [Abstract][Full Text] [Related]
19. Design of a modular immunotoxin connected by polyionic adapter peptides.
Kleinschmidt M; Rudolph R; Lilie H
J Mol Biol; 2003 Mar; 327(2):445-52. PubMed ID: 12628249
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.
Gao W; Tang Z; Zhang YF; Feng M; Qian M; Dimitrov DS; Ho M
Nat Commun; 2015 Mar; 6():6536. PubMed ID: 25758784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]